February 26, 2025
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
Grey’s Anatomy Star Kate Walsh Partners with GRAIL for Multi-Cancer Early Detection Awareness Campaign
Kate Walsh, GRAIL, multi-cancer early detection (MCED), Generation Possible, cancer screening, blood test
FDA updates Boston Scientific’s Accolade pacemaker recall, reporting 832 injuries
United States Food and Drug Administration, Mental Recall, Preventive monitoring, trauma qualifier, Medical Devices, Artificial cardiac pacemaker
Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care
Patient-centered epilepsy care, Holistic epilepsy management, Quality of life in epilepsy, Empowering epilepsy patients, Multidisciplinary epilepsy treatment, Epilepsy patient experiences, Comprehensive epilepsy support
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch
EU, Market, Access, Failed, NR4A2 gene
Eli Lilly makes Zepbound vials cheaper for self-paying patients
self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg
Lava cuts jobs by 30% after key drug discontinued
LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway
Lilly lowers price of Zepbound vials, launches new doses
Eli Lilly, Dosage, Prices, Affordability, Obesity